Page last updated: 2024-08-24

mibefradil and Local Neoplasm Recurrence

mibefradil has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Azimi, I; Dutta, T; Feng, Z; Gueven, N; Maklad, A; Sedeeq, M; Wilson, R1
Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X1

Trials

1 trial(s) available for mibefradil and Local Neoplasm Recurrence

ArticleYear
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
    Neuro-oncology, 2017, 06-01, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult

2017

Other Studies

1 other study(ies) available for mibefradil and Local Neoplasm Recurrence

ArticleYear
T-Type Calcium Channel Inhibitors Induce Apoptosis in Medulloblastoma Cells Associated with Altered Metabolic Activity.
    Molecular neurobiology, 2022, Volume: 59, Issue:5

    Topics: Apoptosis; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cerebellar Neoplasms; Child; Humans; Medulloblastoma; Mibefradil; Neoplasm Recurrence, Local; Vincristine

2022